https://vitasmlab.net

VIRMARK

General Human Antiviral Targeted Library

Human viruses are among the most significant global health threats, causing diseases ranging from mild infections like the common cold to deadly pandemics like HIV/AIDS. They evolve rapidly, evade immunity, and can trigger chronic illnesses. While vaccines prevent many viral infections, antiviral drugs remain critical for treatment—yet options are limited, often targeting only a few viral proteins. Events like recent Ebola virus outbreak exemplifies this challenge, with its high fatality rate and underscore the urgent need for novel antivirals.. Currently, no approved small-molecule drugs exist for many such viruses, as their rapid replication and ability to suppress host immunity make them a formidable targets. Broad-spectrum drugs targeting conserved viral machinery or host dependency factors could combat multiple viruses and preempt outbreaks. Additionally, many viruses lack effective treatments. Advances in structural biology and drug design are acceler- ating discovery, but sustained research is vital to outpace viral evolution and prepare for future threats.





STL023096



STL130458



STL167203

General Human Antiviral Targeted Library (VIRMARK) consists of compounds with potential antiviral activity, which were selected based on similarity to known effectors of various viral proteins. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 28432 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at

irina@vitasmlab.biz

Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!

Empowering Your Research, One Molecule at a Time.